Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jan 20

PMID 33466496

Citations 27

Authors

Shigeo Shimose

Hideki Iwamoto

Masatoshi Tanaka

Takashi Niizeki

Tomotake Shirono

Yu Noda

Naoki Kamachi

Shusuke Okamura

Masahito Nakano

Hideya Suga

Taizo Yamaguchi

Takumi Kawaguchi

Ryoko Kuromatsu

Kazunori Noguchi

Hironori Koga

Takuji Torimura

Affiliations

Soon will be listed here.

Abstract

We aimed to evaluate the impact of alternating lenvatinib (LEN) and trans-arterial therapy (AT) in patients with intermediate-stage hepatocellular carcinoma (HCC) after propensity score matching (PSM). This retrospective study enrolled 113 patients with intermediate-stage HCC treated LEN. Patients were classified into the AT ( = 41) or non-AT group ( = 72) according to the post LEN treatment. Overall survival (OS) was calculated using the Kaplan-Meier method and analyzed using a log-rank test after PSM. Factors associated with AT were evaluated using a decision tree analysis. After PSM, there were no significant differences in age, sex, etiology, or albumin-bilirubin (ALBI) score/grade between groups. The survival rate of the AT group was significantly higher than that of the non-AT group (median survival time; not reached vs. 16.3 months, = 0.01). Independent factors associated with OS were AT and ALBI grade 1 in the Cox regression analysis. In the decision tree analysis, age and ALBI were the first and second splitting variables for AT. In this study, we show that AT may improve prognosis in patients with intermediate-stage HCC. Moreover, alternating LEN and trans-arterial therapy may be recommended for patients below 70 years of age with ALBI grade 1.

Citing Articles

Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.

Moriyama E, Shimose S, Niizeki T, Iwamoto H, Tanaka M, Shirono T Curr Oncol. 2024; 31(10):5821-5831.

PMID: 39451736 PMC: 11506552. DOI: 10.3390/curroncol31100432.

Multiparametric MRI based deep learning model for prediction of early recurrence of hepatocellular carcinoma after SR following TACE.

Wang H, Li J, Ouyang Y, Ren H, An C, Liu W J Cancer Res Clin Oncol. 2024; 150(10):448.

PMID: 39379692 PMC: 11461583. DOI: 10.1007/s00432-024-05941-w.

Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases.

Morsica G, Bertoni C, Hasson H, Messina E, Uberti Foppa C Front Oncol. 2023; 13:1242741.

PMID: 38115904 PMC: 10728594. DOI: 10.3389/fonc.2023.1242741.

Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm,....

Oshita K, Kobayashi T, Namba Y, Fukuhara S, Matsubara K, Takei D BMJ Open. 2023; 13(10):e073797.

PMID: 37798025 PMC: 10565137. DOI: 10.1136/bmjopen-2023-073797.

Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.

Shimose S, Iwamoto H, Niizeki T, Tanaka M, Shirono T, Moriyama E Int J Mol Sci. 2023; 24(18).

PMID: 37762018 PMC: 10530984. DOI: 10.3390/ijms241813715.

References

Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A . Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008; 103(4):914-21. DOI: 10.1111/j.1572-0241.2007.01712.x. View

Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S . Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Hepatol Commun. 2020; 4(8):1218-1228. PMC: 7395064. DOI: 10.1002/hep4.1535. View

Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H . Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol Res. 2019; 49(8):919-928. DOI: 10.1111/hepr.13348. View

Hiraoka A, Kumada T, Michitaka K, Kudo M . Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer. 2019; 8(5):312-325. PMC: 6873026. DOI: 10.1159/000494844. View

Lee I, Hung Y, Liu C, Lee R, Su C, Huo T . A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Int. 2019; 39(9):1704-1712. DOI: 10.1111/liv.14194. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K . Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014; 6:18. PMC: 4156793. DOI: 10.1186/2045-824X-6-18. View

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

10.

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H . Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019; 69(8):1492-1501. PMC: 7398460. DOI: 10.1136/gutjnl-2019-318934. View

11.

Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M . Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncol Lett. 2020; 19(4):2667-2676. PMC: 7068224. DOI: 10.3892/ol.2020.11399. View

12.

Li X, Feng G, Zheng C, Zhuo C, Liu X . Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004; 10(19):2878-82. PMC: 4572123. DOI: 10.3748/wjg.v10.i19.2878. View

13.

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

14.

Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K . Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer. 2019; 8(2):121-129. PMC: 6465715. DOI: 10.1159/000488778. View

15.

Llovet J, Bruix J . Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37(2):429-42. DOI: 10.1053/jhep.2003.50047. View

16.

Dale W, Mohile S, Eldadah B, Trimble E, Schilsky R, Cohen H . Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst. 2012; 104(8):581-9. PMC: 3328422. DOI: 10.1093/jnci/djs145. View

17.

Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H . Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol. 2016; 77(2):243-50. DOI: 10.1007/s00280-015-2892-7. View

18.

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

19.

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

20.

Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O . Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. Liver Cancer. 2016; 5(3):190-7. PMC: 4960353. DOI: 10.1159/000367775. View